9.35
0.24 (2.63%)
| Penutupan Terdahulu | 9.11 |
| Jumlah Dagangan | 457,965 |
| Harga / Pendapatan (P/E Ke hadapan) | 3.46 |
| Harga / Jualan (P/S) | 2.07 |
| Harga / Buku (P/B) | 3.44 |
| Julat 52 Minggu |
| Margin Keuntungan | 16.36% |
| Margin Operasi (TTM) | 8.66% |
| EPS Cair (TTM) | 0.780 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 5.10% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | 57.40% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 63.55% |
| Nisbah Semasa (MRQ) | 1.53 |
| Aliran Tunai Operasi (OCF TTM) | 31.28 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 19.67 M |
| Pulangan Atas Aset (ROA TTM) | 11.35% |
| Pulangan Atas Ekuiti (ROE TTM) | 51.41% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Puma Biotechnology Inc | Bercampur | Bercampur |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -3.0 |
| Purata Bergerak Teknikal | -1.0 |
| Osilator Teknikal | 4.0 |
| Purata | 0.94 |
|
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 15.87% |
| % Dimiliki oleh Institusi | 65.68% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |